LeMaitre Vascular (LMAT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.65
- Estimate
- $0.69
- Surprise
- -5.3%
- Score at report (before → after)
- 5.5 → 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
LeMaitre Vascular (LMAT) missed the $0.69 estimate with adjusted EPS of $0.65 — a clear 5.3% shortfall. TrendMatrix's engine moved from Hold (5.5/10) to Sell at 5.7/10 after the report — the engine's score rose despite the miss.
Coverage in the report window
- LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Gui — benzinga, 2026-11-04
- LeMaitre Vascular Lowers Q4 GAAP EPS Guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 Est; Lowers Q4 Sales Guidance fro — benzinga, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates LMAT Sell at 5.7/10.
2 of the last 4 quarters beat the estimate; this quarter's -5.3% surprise compares with a -2.0% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.4 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: biologic products (53.0%)
- Concentration risk — Product: open surgical procedure devices
- Thin upside margin: 5.9%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $87.92
- Price target
- $93.09
- Stop
- $82.46
- Upside to target
- +5.9%
- Reward-to-risk
- 0.5:1
At 30.8× trailing and 27.7× forward earnings, consensus estimates imply little change in earnings power.
Risk check: trading volume is running 1.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
LMAT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $2.01B
- P/E (fwd)
- 27.7
- P/E (ttm)
- 30.8
- 52-week range
- $78.22–$118.01
- Off 52-week high
- 25.5%
- RSI (14)
- 60
- Volume vs avg
- 1.82×
- Score today
- 5.7/10